Production of IgG-producing hybridomas by in vitro stimulation of murine spleen cells

In vitro immunization of mouse spleen cells for the production of monoclonal IgG1 antibodies using an antigen-specific T helper cell clone (D.10.G4.1)

The in vitro immunization of mouse spleen cells for the production of antigen-specific monoclonal antibodies has been investigated in detail. Using various, previous published in vitro immunization protocols with and without antigen, we were able to show that IgM antibody production was not induced by the antigen. Nevertheless we developed a new in vitro immunization protocol for eliciting antigen-specific monoclonal IgG1 antibodies. Specific antibodies were generated by an antigen-driven immune response which included an immunoglobulin class switch. Co-culture of mouse spleen cells with an activated conalbumin specific T helper cell clone (TH2 D.10.G4.1) in the presence of conalbumin elicited three monoclonal IgG1 antibodies that bound specifically to conalbumin. We conclude that for the in vitro generation of monoclonal antibodies against T cell dependent proteins the addition of antigen activated specific TH2 cell clones is essential.

Rapid generation of monoclonal antibody-secreting hybridomas against African horse sickness virus by in vitro immunization and the fusion/cloning technique

Splenocytes from non-immune mice were stimulated in vitro using an equimolar mixture of factors from mixed lymphocyte reaction (MLR) and from phorbol-12-myristate 13-acetate (PMA) stimulated EL-4 cells, and concomitantly immunized with inactivated African horse sickness virus (AHSV) antigen serotype 4 or viral proteins 2 and 5 from AHSV serotype 9. Fusion with NSO myeloma cells was performed five days after primary or secondary stimulation/immunization. The record of hybridoma growth after a standard method of fusion, expansion of cells and subsequent cloning was compared with a fusion/cloning method in which cells were cloned within 2 to 3 days of the fusion event. Detection of antigen specific antibodies in the hybridoma culture supernatants was successful only with cells derived from primary stimulation/immunizations. Antibodies were detected using an indirect ELISA with the immunizing antigen coated on to the surface of the plates. Monoclonal hybridomas were isolated within 2 to 3 weeks using the fusion/cloning method, compared with the standard method, where it took 4 to 5 weeks. Although the total number of clones isolated from the fusion/cloning method was less than that obtained through the standard method, the yield of specific antibody-producing hybridomas as a percentage of the total picked was often more efficient with the fusion/cloning method. With respect to the immunoglobulin isotype produced, not all of the antibodies could be classified by the ELISA system used; 14% of anti-AHSV positive clones were identified as IgG-secreting cells, 25% as IgM-secreting, 18% were cross-reacting with IgG and IgM, and 43% could not be classified. Similar results in all aspects of the work were obtained whether a crude infected cell extract or purified outer capsid polypeptides VP2/5, from serotype 4 and serotype 9 respectively, were used.

Production of monoclonal antibodies specific for African swine fever virus following in vitro primary immunization of mouse splenocytes in the presence of stimulated T lymphocyte supernatants

Splenocytes from non-immune mice were stimulated in vitro using a kit of cytokine preparations (obtained from murine MLR and EL-4 cell cultures), and concomitantly immunized with African swine fever (ASF) virus antigen. In addition, fusions were performed at 5 days after primary or secondary stimulation/immunization. The detection of specific antibodies in the culture supernatants was not successful. In contrast, specific antibody-producing hybridomas could be generated, and this was at least comparable to a standard in vivo immunization regime, even though the optimum fusion ratio employed with these in vitro immunized splenocytes was one which is not optimum when in vivo immunized lymphocytes are used. Consequently, it would appear that hybridoma generation is a more sensitive method than the direct measurement of antibody at detecting in vitro primary immune responses. After primary in vitro immunization, the majority of immunoglobulins produced were apparently of the IgG isotype, with only 8-17% clearly IgM. These antibodies were mainly against VP73 (the major viral envelope protein) as expressed on viral antigen extracted from infected cells, although other specificities were also found. This demonstrated, by in vitro means, that the VP73 carried dominant immunogenic epitopes on ASF virus. Such observations show that the in vitro responses were closely related to those which have been detected in vivo.

Increased yields of IgG2a- and IgG3-secreting hybridomas after fusion of B cells from mice with autoimmune diseases

Hybridoma technology has made the production of antigen-specific monoclonal antibodies feasible and almost routine, but the production of certain biologically desirable antibody isotypes has remained difficult. Three strains of autoimmune mice (MRL/l, NZB, and BXSB) were compared to a normal strain (BALB/c), in fusions with a BALB/c myeloma (NS-1) in order to study the rescue of relevant isotypes with the desired antigenic specificities. Mice from these four strains were immunized with colon carcinoma cells, and the hybridoma supernatants from thirty fusions were analyzed for (1) reactivity with cell surface determinants on the immunizing cell line; and (2) Ig class and subclass isotypes. We found that compared to BALB/c mice, MRL/l mice produced greater numbers, and NZB and BXSB mice comparable numbers, of cell surface-reactive hybridoma clones per fusion. MRL/l mice produced the largest number and highest percentage of cell-surface reactive IgG2a (22.4%) and IgG3 (10.6%) producing clones, followed by NZB mice which produced predominantly IgG2a clones (12.3%). BXSB mice, which have latent autoimmune disease, showed no significant difference from normal BALB/c controls (IgG2a:0.7% and IgG3:1.9% vs. IgG2a:4.8% and IgG3:4.8%). The increase in IgG2a and IgG3 clones derived from MRL/l mice was age-dependent, correlating with the age at which abnormal proliferation of T cell and splenic enlargement occurs (2-4 months). We conclude that MRL/l mice are useful for generating monoclonal antibodies of the IgG2a or IgG3 isotype, provided fusions are performed at the time of maximal lymphoproliferation.

Xenopus oocytes as immunological vectors to produce monoclonal antibodies to rat brain antigens

A novel approach was developed to raise a panel of monoclonal antibodies (mAb) against brain antigens using Xenopus oocytes as immunological vectors. Xenopus oocytes were injected to express proteins encoded by brain-derived mRNA extracted from rat cerebral cortex. A crude membrane preparation from mRNA-injected oocytes was then used to immunize mice previously rendered immunotolerant to native oocyte membranes. mAb reacting with cryostat cut sections from rat brain were selected and further characterized by immunohistological and immunobiochemical techniques. Several mAb recognized brain specific antigens, including some that were cell type specific and others that revealed a regional binding pattern. A particular group of antibodies recognized an epitope localized exclusively to the cerebellar pinceau terminals. Although some of the hybridomas found in this panel may be products of natural autoreactive lymphocytes, the presence of a specific immune response to mRNA expression products is discussed. These results indicate that mRNA injected oocytes are useful tools to raise mAb to study the molecular diversity of the nervous system.

In vitro immunization of rat spleen lymphocytes with Forssman glycosphingolipid antigen and the generation of a monoclonal antibody

A procedure for in vitro immunization of splenic lymphocytes with a glycolipid antigen is described. Culture medium supernatant of ConA- and PHA-stimulated spleen cells and that of Con A-stimulated human Jurkat T cell line (IL-2-rich medium) were used as sources of cytokines to support T and B cell stimulation, and anti-mu was used to support B cell differentiation. Unprimed rat spleen cells (2 x 10(6)/ml) were stimulated with 2 micrograms/ml Forssman glycolipid antigen coupled to Sepharose for 4 days. The cells were fused with a mouse myeloma cell line P3-X63-Ag8-U1. At initial screening, 12% of the colony forming wells were secreting specific antibody. After cloning, a stable hybridoma cell line (designated 4C3) was established which secreted a monoclonal IgM antibody directed against the carbohydrate moiety of Forssman glycosphingolipid (GalNAc alpha 1-3GalNAc beta 1-3Gal alpha 1-4Gal beta 1-4Glc-ceramide).

In vitro stimulation of nonimmunized, naturally infected rat spleen cells for the production of Mycoplasma pulmonis-specific monoclonal antibodies

Spleen cells derived from rats naturally-infected with Mycoplasma pulmonis were stimulated in vitro, and then fused with a mouse myeloma cell line. The resulting hybridomas were screened for mycoplasma-specific Mabs by ELISA and for hemolysis-blocking activities. Fusions performed with in vitro-treated spleen cells yielded larger numbers of growth-positive wells and antibody secreting cells than untreated spleen cells from the same animals. Hybridomas derived from naturally-infected animals gave a higher percentage of hemolysin-specific monoclonal antibodies than did hyperimmunized animals. This indicated that B cell priming during mucosal infections can produce antigen-primed spleen cells. Stimulation of these cells in vitro can result in monoclonal antibodies against antigens not normally recognized during immunization with in vitro grown pathogenic bacteria.

In vitro stimulation of immune spleen cells enhances the number of anti-lipid A-producing hybridomas

An in vitro stimulation method for the generation of hybridomas producing antibodies with specificity for the weakly immunogenic lipid A is described. Conditions influencing in vitro stimulation of immune spleen cells were investigated. Depending on the experimental conditions the percentage of specific antibody-producing hybridomas varied between 0 and 39%. Most successful was stimulation with both antigen and the synthetic adjuvant muramyl dipeptide (MDP) for 3 days. In vitro stimulation of spleen cells from animals classically immunized with Salmonella Re mutant enhanced the number of lipid A-specific IgG-producing hybridomas from six after direct fusion to 17 after stimulation. These experiments indicate that the synergistic action of antigen and MDP is caused by preferential action on antigen selected B cells.